Chief Executive of Sanofi-Aventis, Chris Viehbacher, stated: “we are interested in the Japanese generic market and we are in a discussions with a partner but we can’t officially confirm anything because we are not quite ready for that”.
Chris Viehbacher also spoke about Sanofi’s plans to become the fifth largest drugmaker in Japan in five years.
However, according the publication Nikkei Business Daily, Sanofi is planning to invest $56 million for a 5% stake in Nichi-iko. The newspaper has also reported that the two pharmaceutical companies will form a joint venture to share technology to develop new generics and import Sanofi products.
It is no surprise that the Japanese generics market is becoming more and more interested in big pharma – after all, the Japanese government has set a target to increase generics by 20% in the year to March 2013.
Looking for a job in the pharmaceutical industry? Search our current pharmaceutical jobs now.